Inhibikase Therapeutics (NASDAQ:IKT) Trading Up 6.9% – What’s Next?

Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) traded up 6.9% during mid-day trading on Wednesday . The company traded as high as $1.72 and last traded at $1.71. 619,960 shares traded hands during trading, a decline of 4% from the average session volume of 643,198 shares. The stock had previously closed at $1.60.

Analyst Ratings Changes

Several research firms recently weighed in on IKT. Cantor Fitzgerald raised Inhibikase Therapeutics to a “strong-buy” rating in a research note on Thursday, December 11th. Lifesci Capital upgraded Inhibikase Therapeutics to a “strong-buy” rating in a research report on Monday, December 1st. Zacks Research upgraded shares of Inhibikase Therapeutics to a “hold” rating in a research report on Tuesday, December 2nd. HC Wainwright raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a research note on Friday, December 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Thursday, January 22nd. Three analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy”.

Inhibikase Therapeutics Stock Up 6.9%

The stock has a market cap of $128.56 million, a P/E ratio of -4.38 and a beta of 0.84. The business’s fifty day moving average price is $1.69.

Inhibikase Therapeutics (NASDAQ:IKT) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.